BigCapital beta

Moscow Exchange · GEMA · RAS

Mezhdunarodnyy Meditsinskiy Tsentr Obrabotki i Kriokhraneniya Biomaterialov: revenue, profit and cash flow

In 2024, Mezhdunarodnyy Meditsinskiy Tsentr Obrabotki i Kriokhraneniya Biomaterialov had revenue of ₽349M and a net profit of ₽151M, according to its single-entity RAS statements (without subsidiaries). Here: 2 years of annual reports since 2023, each linked to the original document.

Revenue, 2024

₽349M+23.0%

change against 2023

Net profit
₽151M
43.4% of revenue
Operating cash flow
₽248M
Capital expenditure
₽10.6M
Free cash flow
₽237M
operating cash flow minus capital expenditure
Net debt
−₽36.8M
borrowings minus cash; leases not included
Dividends paid
₽153M
Total assets
₽1.24B
Equity
₽304M

Where the money goes

Of every ₽100 of revenue in 2024, Mezhdunarodnyy Meditsinskiy Tsentr Obrabotki i Kriokhraneniya Biomaterialov spent ₽16.8 on the cost of its products and services and ₽32.0 on running the business (₽32.0 of it on selling and administration); ₽0.0 went to income tax, ₽7.7 went to interest and other items, and ₽43.4 was left as net profit.

2024 · rubles · share of revenue
In 2024AmountOf revenue
Revenue₽349M100.0%
Cost of revenue−₽58.7M16.8%
Gross profit₽290M83.2%
Sales & admin−₽112M32.0%
Operating profit₽178M51.1%
Income tax₽-00.0%
Interest and other, net−₽26.9M7.7%
Net profit₽151M43.4%

Revenue and net profit

Revenue went from ₽284M in 2023 to ₽349M in 2024.

RevenueNet profit
Rubles, as reported (RAS); years without a report are left out.

Operating cash flow, capex and free cash flow

Free cash flow (operating cash flow minus capital expenditure) was ₽237M in 2024, 68.0% of revenue.

Operating cash flowCapital expenditureFree cash flow
Rubles, as reported (RAS); years without a report are left out.

What it owns and who paid for it

At the end of 2024, Mezhdunarodnyy Meditsinskiy Tsentr Obrabotki i Kriokhraneniya Biomaterialov had ₽1.24B of assets, ₽277M of it in cash. They were paid for by ₽240M of borrowings, ₽692M of other liabilities and ₽304M of shareholders' equity: equity is 24.6% of the assets.

End of 2024 · rubles · share of assets · sizes across years on a square-root scale

Net debt

At the end of 2024, Mezhdunarodnyy Meditsinskiy Tsentr Obrabotki i Kriokhraneniya Biomaterialov had more cash than borrowings: net cash of ₽36.8M.

Net debt
Rubles, as reported (RAS); years without a report are left out.

Dividends paid

In 2024, Mezhdunarodnyy Meditsinskiy Tsentr Obrabotki i Kriokhraneniya Biomaterialov paid ₽153M in dividends, 101% of its net profit for the year.

Dividends paid
Rubles, as reported (RAS); years without a report are left out.

Mezhdunarodnyy Meditsinskiy Tsentr Obrabotki i Kriokhraneniya Biomaterialov: annual figures

YearRevenueOperating profitNet profitOperating cash flowCapital expenditureFree cash flowNet debtDividends paidTotal assetsEquity
2024₽349M₽178M₽151M₽248M₽10.6M₽237M−₽36.8M₽153M₽1.24B₽304M
2023*₽284M₽149M₽126M₽224M₽14.2M₽210M₽43.8M₽123M₽1.28B₽441M

* Taken from the comparative column of the next year's report: the year's own report was not available to us.

Original reports

Every figure on this page comes from the company's own annual statements. The documents, by year:

How to read these numbers

Source: annual financial statements published by Mezhdunarodnyy Meditsinskiy Tsentr Obrabotki i Kriokhraneniya Biomaterialov (links to the original documents above). Figures read from the documents by BigCapital.

For information only, not investment advice.

Language

EnglishBahasa IndonesiaDeutschEspañolFrançaisItalianoNederlandsPolskiPortuguêsTürkçeРусскийУкраїнська日本語한국어简体中文